Given the current lack of FDA-approved treatments for NAFLD, this study underscores the promise of SGLT2 inhibitors as a novel therapeutic approach, particularly for patients with comorbid metabolic conditions. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.